Targeting Solid Tumors With Potassium Channel Activators: A Return to Fundamentals?

The document discussed the pharmacological potential of nicotinamide and minoxidil, both potassium channel activators, in targeting solid tumors. Nicotinamide had shown promising but unconfirmed results as a radiosensitizer in the ARCON therapeutic strategy, which combines accelerated radiotherapy with carbogen breathing and nicotinamide. Minoxidil, although not previously considered by radiotherapists, was suggested to have potential based on recent pathophysiological insights. The authors proposed a new perspective on using these two established molecules to target solid tumors.